Diffuse Large B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Diffuse Large B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating CAR-20/19-T cells in relapsed or refractory B-cell malignancies, including multiple non-Hodgkin lymphoma…
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies [Phase 1]
A Phase 1 clinical trial is investigating LV20.19 CAR T-cells in combination with pirtobrutinib for relapsed or refractory B-cell malignanci…
-
CLINICAL_TRIALS research · 2026-02-20Clinical Trial Update: A Study of APG-3288 in Relapsed/Refractory Blood Cancers [Phase 1]
Phase 1 study of APG-3288 in relapsed/refractory hematologic cancers; the trial is not yet recruiting.
-
CLINICAL_TRIALS research · 2026-02-19Clinical Trial Update: Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
This clinical trial update reports ongoing Phase 1/2 testing of the combination epcoritamab plus ibrutinib for relapsed or refractory aggres…
-
CLINICAL_TRIALS research · 2026-02-19Clinical Trial Update: Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas [Phase 1]
Phase 1 trial evaluating pomalidomide with dose-adjusted EPOCH, with or without rituximab, for HIV-associated lymphomas; recruitment is ongo…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
A pharmacokinetic study is evaluating how crushing venetoclax tablets and dissolving them in solution affects drug exposure, to assess alter…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCL [Phase 1, Phase 2]
This is an early-phase clinical trial evaluating polatuzumab vedotin in combination with rituximab and chidamide for newly diagnosed elderly…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma [Phase 2]
Phase 2 study evaluating the safety and efficacy of Glofitamab in combination with Rituximab-CHOP in untreated diffuse large B-cell lymphoma…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma [EARLY_Phase 1]
This is an early-phase (Phase 1) clinical trial update for Iomab-ACT, which combines 131-I-labeled apamistamab with CD19-targeted CAR T-cell…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: This Clinical Trial is a Single-arm, Non-randomized Pilot Trial to Determine the Safety of Administering Autologous Anti-C19 Cells (ARI-0001) and the Feasibility of Local CAR-T Cell Production in Patients Over 18 Years of Age With Relapsed/Refractory (R/R) CD19+ Hematologic Malignancies, Including R [NA]
A single-arm, non-randomized pilot trial to evaluate the safety of autologous anti-CD19 CAR-T cells (ARI-0001) and the feasibility of local …
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma [Phase 2]
A Phase 2 trial update from Northwestern University evaluating the combination of epcoritamab and lenalidomide in patients with refractory o…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma
A real-world study is evaluating subcutaneous epcoritamab in adults with diffuse large B-cell lymphoma and follicular lymphoma and is curren…
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. [Phase 1]
A Phase 1 clinical trial evaluating oral LP-168 in relapsed or refractory B-cell malignancies is recruiting. Target conditions include CLL/S…
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL [Phase 1, Phase 2]
A Phase 1/2 study of MT-2111 in relapsed or refractory Diffuse Large B-Cell Lymphoma is ongoing, with the trial status shown as active but n…
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: Study of SGR-1505 in Mature B-Cell Neoplasms [Phase 1]
Schrödinger's SGR-1505 is being evaluated in a Phase 1 trial across multiple mature B-cell neoplasms and is currently recruiting. The study …
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies [Phase 1]
Phase 1 clinical trial from Mayo Clinic is evaluating BAFFR-based CAR-T cells with lymphodepletion (fludarabine and cyclophosphamide) for re…
-
CLINICAL_TRIALS research · 2026-02-12Clinical Trial Update: Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets [Phase 1]
This clinical trial update describes the ongoing Phase 1 study of ABBV-525 tablets in adults with B-cell malignancies. The study evaluates a…
-
CLINICAL_TRIALS research · 2026-02-12Clinical Trial Update: Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial) [Phase 2]
Phase 2 trial evaluating selinexor in combination with the R-CHOP regimen as first-line therapy for TP53-mutated diffuse large B-cell lympho…
-
CLINICAL_TRIALS research · 2026-02-12Clinical Trial Update: Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma [Phase 3]
A Phase 3 clinical trial compares golcadomide plus R-CHOP to placebo plus R-CHOP in previously untreated high-risk diffuse large B-cell lymp…
-
CLINICAL_TRIALS research · 2026-02-10Clinical Trial Update: This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma [Phase 1]
Phase 1 clinical trial assessing the safety of LTZ-301 in patients with various forms of non-Hodgkin lymphoma, currently recruiting.
-
CLINICAL_TRIALS research · 2026-02-10Clinical Trial Update: Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study [Phase 1, Phase 2]
A Phase Ib/II study evaluating lisatoclax in combination with standard regimens R-CHOP or Pola-R-CHP for untreated diffuse large B-cell lymp…
-
CLINICAL_TRIALS research · 2026-02-09Clinical Trial Update: CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL [Phase 2]
A Phase 2 clinical trial is evaluating a CRP regimen for elderly patients with previously untreated double-positive diffuse large B-cell lym…
-
CLINICAL_TRIALS research · 2026-02-06Clinical Trial Update: Italian Real-World Study of Epcoritamab in Relapsed or Refractory DLBCL
The document provides details of an Italian real-world study evaluating epcoritamab in relapsed or refractory diffuse large B-cell lymphoma.
-
CLINICAL_TRIALS research · 2026-02-06Clinical Trial Update: Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma [Phase 2]
Ongoing Phase 2 trial evaluating nivolumab in combination with DA-REPOCH chemotherapy for aggressive B-cell non-Hodgkin lymphomas, including…
-
CLINICAL_TRIALS research · 2026-02-05Clinical Trial Update: Modified R-MINE Regimen vs. R-GemOx Regimens on the Treatment of Late Relapsed DLBCL [NA]
A clinical trial comparing modified R-MINE versus R-GemOx regimens for late-relapsed diffuse large B-cell lymphoma; the study is not yet rec…